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African trypanosomiasis is an emergent disease with sig-
nificant social and economical impact in 36 African coun-
tries. Available drug regimens are very limited and highly
toxic so the development of a vaccine would be extremely
advantageous. Since the parasite has the ability of mis-
leading the immune response through antigenic variation
of its surface coat the development of vaccine was thought
to be highly unlikely. However research focused on the
identification of invariant components to be used as ther-
apeutic targets and the evolution of DNA vaccine technol-
ogy bring this objective into the realms of possibility.
Ten DNA vaccine prototypes were constructed encoding
ISG (invariant surface glycoprotein) and TSA (trans-siali-
dase) genes from Trypanosoma brucei. These were linked to
different targeting sequences to direct the protein to the
major antigen processing pathways: (1) LAMP-1 signal
targets the protein to the lysosomes (pISGlamp,
pTSAlamp); (2) E1A directs the protein to the ER
(pe1aISG, pe1aTSA) (3) secretion signal promotes protein
secretion (pscISG, pscTSA) (4) E1A and LAMP combined
(pe1aISGlamp, pe1aTSAlamp).
The candidate vaccines were tested alongside two controls
(PBS and pVAX1GFP). Groups of six CD1 female mice
were immunised 50 μg DNA (or control) by intramuscu-
lar injection. Animals were killed 28 days post-immuniza-
tion and the right popliteal and axillary lymph-nodes
removed for mRNA extraction and histological analysis.
In a second experiment the delayed hypersensitivity
response (DTH) to trypanosome lysate was assessed. At 14
days post immunization mice mice were injected with 25
μg of trypanosome lysate into the right footpad. The con-
tralateral footpad was injected with 25 μl saline. Footpad
thickness was measured at 0, 24 and 48 hours after injec-
tion.
The expression of IFN-γ, TNF-α, IL-1β, IL-2, IL-4, IL-10
and IL-6 in lymphoid tissue was assessed using reverse
transcriptase-PCR analyses. Expression levels were applied
to rank the candidate vaccines on a scale of 1–12, 1 being
the lowest and 12 the highest expression; pe1aISG, pIS-
Glamp, pTSAlamp and pe1aISGlamp groups obtained the
best scores. DTH analysis revealed an increase in footpad
thickness in mice immunised with all ISG plasmids, pTSA,
pscTSA and pe1aTSA compared to PBS.
Histological analysis was used to determine the degree of
activation present within the lymph-nodes. pISGlamp
and pe1aISGlamp were found to induce the highest levels
of stimulation.
On the basis of these experiments pISGlamp,
pe1aISGlamp, pe1aISG and pTSAlamp were selected as
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the most promising vaccines. Challenge assays will deter-
mine their effect on progression of the disease.Page 2 of 2
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